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Abstract: Cytochrome P450 3A4 is the most significant enzyme in metabolism of medications. Flavonoids are common secondary plant 
metabolites found in fruits and vegetables. Some flavonoids can interact with other drugs by inhibiting cytochrome P450 enzymes. Thus, the 
objective of this study was to determine inhibition kinetics of cytochrome P450 3A4 by flavonoids: acacetin, apigenin, chrysin and pinocembrin. 
For this purpose, testosterone was used as marker substrate, and generation of the 6β-hydroxy metabolite was monitored by high performance 
liquid chromatography coupled with diode array detector. IC50 values, inhibition constants, and rates of inhibition were determined. IC50 values 
ranged between 0.6 and 11.4 µM. The strongest inhibitor was chrysin (IC50 0.6 µM, inhibition constant 0.6 µM, inhibition rate constant 0.065 
min–1, inhibition efficacy 0.108 min–1 µM–1). Compared to other flavonoids analyzed, chrysin’s inhibitory effect can be attributed to the 
hydrophobic nonsubstituted B ring, as well as rigidity of the structure. When foods rich in chrysin are consumed, e.g. honey and propolis, 
chrysin can cause food-drug interactions. Further in vitro studies are needed to determine the reactive intermediate responsible for inactivation 
of cytochrome P450 3A4 enzyme, as well as in vivo studies to determine possible clinical significance of this inhibition. 
 





YTOCHROMES P450 are the most important metabolic 
enzymes responsible for over 94 % of metabolic 
reactions of drugs and other xenobiotics.[1] These enzymes 
do not fit to a lock (enzyme) and key (substrate) enzyme 
model. Rather, every cytochrome P450 can have numerous 
substrates and each xenobiotic can be a substrate  
to multiple cytochrome P450 enzymes.[2] Consequently, 
interactions between different xenobiotics can occur,  
e.g. drug-drug interactions that can have repercussions  
on the outcome of the pharmacotherapy as well as possible 
side-effects. 
 Most common reason for metabolic drug-drug 
interactions are inhibitions of cytochromes P450.[3] These 
inhibitions can be reversable, most commonly competitive, 
and are regarded as less severe, as an adjustment of the 
medication dose will usually resolve possible unwanted 
effects of the interaction.[3] However, in the case of 
irreversible inhibition, a simple adjustment of the dose is 
not possible, and a drug, the perpetrator of the inhibition, 
needs to be discontinued and preferably replaced. If  
an irreversible inhibition is observed, enzyme activity 
diminishes, and new copies of the enzyme have to be 
expressed for the enzyme activity to be recovered 
completely. This process can take from a few days to a  
few weeks, depending of the metabolic enzyme.[3] 
 While metabolic drug-drug interactions are of 
significant interest, food-drug interactions have just come 
into focus.[4,5] Flavonoids, as the most common secondary 
metabolites found in higher plants, are constituents of daily 
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for over a century when they were discovered as vitamin 
P.[7] It has been shown that they have antioxidant, anti-
inflammatory, hepatoprotective, antimicrobial, cardio-
protective, and other pharmacological properties.[6,8] The 
major issue of their application in vivo is their 
bioavailability. However, it has been shown that some 
flavonoids, e.g. chrysin, can achieve submicromolar 
concentrations in plasma and some flavonoids, as soya 
isoflavones, hesperetin and diosmetin, have been in 
commercial use as dietary supplements.[9] 
 Cytochrome P450 3A4 is the most significant 
cytochrome P450 enzyme as it metabolizes about one third 
of the drugs.[1,10] In the previously published screening 
study, it has been shown that acacetin, apigenin, chrysin 
and pinocembrin are the most prominent inhibitors of 
human cytochrome P450 3A4 at 1 µM concentration.[11] 
Flavanone pinocembrin (Figure 1.) reduces the enzyme 
activity by 50 %, while flavones acacetin, apigenin and 
chrysin reduce the enzyme activity to 5 %, 24 % and 17 %, 
respectively.[11] 
 The inhibition of P450 3A4 by acacetin, apigenin, 
chrysin and pinocembrin is not well characterized, and, if 
available, is reported as IC50 value. The IC50 values are 
dependent of the type of inhibition (direct, time and 
metabolism dependent), as well as experimental setup. 
Thus, the objective of this study was to determine 
metabolism dependent inhibition kinetics, inhibition 
constants and rates of inhibition of P450 3A4 by the 
aforementioned flavonoids. As these flavonoids have 
different structural features (Figure 1.): presence or 
absence of double bond at the position C2-C3, 
hydroxylation of B ring and methylation of hydroxyl groups, 




Flavonoids used in this study (acacetin, apigenin, chrysin, 
and pinocembrin) were acquired commercially from Sigma-
Aldrich (St. Louis, MO, USA).  
 Recombinant cytochromes P450 3A4 coexpressed 
with NADPH cytochrome P450 reductase and cytochrome 
b5 in baculosomes were obtained from Thermo Fisher 
Scientific, Waltham, MA, USA.  
 Glucose-6-phosphate (G6P), glucose-6-phosphate 
dehydrogenase (G6PD) and NADP disodium salt were 
purchased from Sigma Aldrich. Potassium phosphate (p.a.) 
and dichloromethane (p.a.) were purchased from Kemika 
d.d. (Zagreb, Croatia). Methanol for chromatography was 
purchased from Merck KGaA (Darmstadt, Germany). Ultra-
pure water was produced using Arium comfort combined 
water production system from Sartorius AG (Goettingen, 
Germany). 
Incubations for Determination of 
Inhibition Kinetics 
To achieve the objective of this study, testosterone was 
used as the marker substrate. Generation of the 6β-
hydroxy metabolite, that reflected residual enzyme 
activity, was monitored by high performance liquid 
chromatography coupled with diode array detector (HPLC-
DAD).[12] For different concentrations of flavonoid, residual 
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enzyme activity was determined after different periods of 
incubation. This data was used to construct Michaelis-
Menten curve, and inhibition constants and rate of 
inhibition were determined. The results were assessed in 
the light of current guidelines on inhibition studies.[13]  
 Evaluation of enzyme kinetics was conducted using 
baculosomes of recombinant cytochrome P450 3A4 
coexpressed with NADPH cytochrome P450 reductase and 
cytochrome b5. A range of flavonoid aglycons concen-
trations from 0.01 to 20 μM was prepared; appropriate 
aliquots of 20 mM flavonoid solutions were transferred to 
glass tubes and evaporated until dry on a water bath 
equipped with mechanical shaking. After solvent evapor-
ation, a 100 μL incubation mixture was prepared in each of 
the tubes by adding cytochrome P450 baculosomes  
(5 pmol), 50 mM potassium phosphate buffer pH 7.4, and 
ultra-pure water. Generating system containing glucose-6-
phosphate, NADP+ and glucose-6-phosphate dehydrogen-
ase in a ratio 100:50:2 (V/V/V) was used as a source of the 
coenzyme (15 % volume in final incubation, V/V), and its 
addition marked the beginning of the reaction. Pre-
incubations were conducted in duplicate for zero, 5, 10, 15, 
20 and 25 minutes.[14] 
 After the appropriate time period, the residual 
enzyme activity was tested by adding 1 μL of testosterone 
solution (final concentration 200 μM). For determination of 
IC50 values, preincubation was set to 15 minutes. 
Testosterone served as the marker substrate of cyto-
chrome P450 activity. The reaction was quenched by 
adding 1 mL of cold dichloromethane. Reaction tubes were 
centrifuged at 1900 g (3000 rpm) for 10 minutes. The 
dichloromethane layer was transferred into a HPLC vial, 
and the organic solvent was evaporated under a stream of 
nitrogen. Dry residues were dissolved in methanol (30 μL) 
and analyzed by HPLC-DAD.[12] 
HPLC-DAD Analysis 
High performance liquid chromatography coupled with 
diode array detection (Agilent 1100 instrument, Santa 
Clara, CA, USA) was used for the analysis of testosterone 
and the 6β-hydroxy metabolite. A C18 analytical column 
(Agilent Zorbax SB C18 column 4.6 × 250 mm, 3 μm) was 
used for isocratic analysis with a mixture of 64 % CH3OH/ 
36 % H2O (V/V) at a flow rate of 1.0 mL/min. Analytes were 
detected at 240 nm, and the amount of generated 6β-
hydroxy testosterone was determined as the area under 
the curve based on the calibration curve of the standard.[12] 
Determination of Enzyme Inhibition 
Parameters 
All incubations were conducted in duplicate. The results 
were expressed as the amount of generated metabolite 
based on HPLC-DAD analysis (vide supra). Based on these 
results, inhibition rates were determined and used for 
calculation of the major parameters of enzyme inhibition 
kinetics (inhibition constant and inhibition rate constant) 
based on the Michaelis-Menten equation. Non-linear three 
parameters sigmoidal-logistic equation was used for IC50 
calculations. Program R (The R Project for Statistical 
Computing, Vienna, Austria) was used for calculations. 
 
RESULTS AND DISCUSION 
In the previously published screening study, it was shown 
that acacetin, apigenin, chrysin, and pinocembrin inhibit 
human cytochrome P450 3A4 at 1 µM concentration.[11] 
Herein, we have characterized the inhibition kinetics and 
determined IC50 values inhibition constants (KI), and rates 
of inhibition (kinact) for each of the aforementioned 
flavonoids. The strongest inhibitor was chrysin (IC50 0.6 µM, 
inhibition constant 0.6 µM, inhibition rate constant 0.065 
min–1, inhibition efficacy 0.108 min–1 µM–1). 
 Since the inhibition was characterized as 
metabolism-dependent, the first objective herein was to 
determine the inhibitory concentrations IC50 (Figure 2.). For 
this purpose, flavonoids were first preincubated with the 
cytochrome P450 3A4 enzyme for 15 minutes, after which 
the residual activity was determined using testosterone as 
the marker substrate. 
 Chrysin had the lowest IC50 value. This is in 
agreement with the fact that a 1 µM concentration of 
chrysin reduced the enzyme activity by 95 %, indicating that 
the IC50 value is in a submicromolar range.[11] Herein, we 
obtained a value of 0.6 ± 0.5 µM. Acacetin and apigenin had 
around twentyfold higher IC50 values, 10.9 ± 0.3 µM and 
11.4 ± 0.4 µM, respectively. In the previously conducted 
molecular docking study, it was shown that chrysin has a 
higher binding affinity to cytochrome P450 3A4 as a neutral 
molecule, exposing the B ring to the iron in the active center 
of the enzyme.[11,15] This confirms that cytochromes P450 
tend to metabolize more lipophilic species.[3] By exposing the 
B ring to the cytochrome P450 active site, a reactive 
intermediate responsible for inactivation can be generated. 
 Acacetin and apigenin differ from chrysin as they 
have a methoxy and a hydroxy group, respectively, at the 
4’ position of the B ring. Oxygen at the 4’ position probably 
interacts with the ferric ion in the active site of the enzyme 
and thus tends to inhibit enzyme activity reversibly as a 
ligand, which has also been reported.[15] Consequently, the 
observed IC50 values for acacetin and apigenin were higher 
when compared to chrysin. 
 Interestingly, pinocembrin had around tenfold 
higher IC50 value of 5.0 ± 0.6 µM when compared to chrysin 
(0.6 ± 0.5 µM). Pinocembrin belongs to the flavanone class 
while chrysin is a flavone, and the only difference in their 
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pinocembrin vs. a double C2=C3 bond in chrysin. A double 
bond in chrysin makes the structure rigid, and no energy 
loss is observed while binding to the active site. 
 Acacetin is one of the major polyphenols present in 
honey, which is believed to be associated with the 
prevention of heart disease.[16] Different studies indicate 
beneficial effects this flavonoid shows. In addition to the 
prevention of heart disease, its antioxidant, anti-
inflammatory and antiplasmodial properties have also 
been shown.[17,18] Additionally, studies indicate its 
antiproliferative properties on different types of tumor 
cells present in the liver, prostate, and lungs.[19] On a rat 
cytochrome P450 3A subfamily it was determined that 
acacetin inhibits the enzyme with a IC50 value of 8.2 μM, 
using midazolam as the marker substrate.[20] This is similar 
to the IC50 value of 10.9 ± 0.3 µM reported herein. 
Apigenin is one of the most present flavonoids in 
food, especially in parsley.[21] As reported in the review by 
Ross and Kasum[21], in vitro studies indicate a significant 
role of apigenin in the prevention of malignancies and 
cardiovascular diseases as well as the stimulation of the 
immune system. The stated antitumor properties of 
apigenin are evident in inhibiting the growth of melanoma 
cell cultures, therefore its use in various therapeutic 
combinations against metastatic melanoma has been 
studied.[22] Apigenin has been shown to inhibit P450 3A4 in 
an assay using 7-benzyloxy-4-trifluoromethylcoumarin as 
the marker substrate with an IC50 value of 1.8 µM.[23] 
Another group obtained an IC50 value of 31 ± 8 µM for 
apigenin using 7-benzyloxymethyloxy-3-cyanocoumarin as 
the marker substrate of cytochrome P450 3A4.[24] Use of 
different substrates for determining cytochrome P450 3A4 
enzyme activity can explain observed differences in IC50 
values between studies. As the cytochrome P450 3A4 has a 
large active site when compared to other human liver 
cytochromes P450, use of at least two marker substrates is 
advisable for the assessment of inhibition kinetics.[3,13] 
 Chrysin is naturally present in honey, but also in 
various plants and propolis.[25] Its anti-inflammatory and 
antioxidant effects are well documented.[26,27] Its 
chemoprotective effects are increasingly being inves-
tigated, and chrysin is believed to exert its effect by 
inducing apoptosis. Chrysin has shown positive in vitro 
effects on cervical cancer, leukemia, prostate and breast 
cancer, as well as colon cancer.[28,29] Chrysin has been 
shown to inhibit cytochrome P450 3A4 in an enzyme 
activity assay using 7-benzyloxymethyloxy-3-cyano-
coumarin as a the marker substrate, and the obtained  
IC50 value was 95 ± 31 µM.[24] In contrast, when 
testosterone was used as the marker substrate, IC50 value 
was determined to be 0.9 µM, similar to this study (0.6 ± 
0.5 µM).[30] 
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 Pinocembrin modulates inflammatory responses, 
and there is a potential for its use in the treatment of 
ischemic stroke and similar clinical conditions.[31] In 
addition, its antifungal activity has been thoroughly 
described, as well as the induction of apoptosis in colon 
cancer cells.[32] While its in vitro pharmacological effects 
have been extensively studied, this is not the case with 
inhibition of cytochrome P450 3A4 enzyme. Herein, we 
have reported an IC50 value of 5.0 ± 0.6 µM. 
 Aforementioned results of inhibition assays have 
been expressed as IC50 values. As IC50 values are depend on 
the experimental setup further characterization of 
inhibition is needed. Thus, we have analyzed inhibition 
kinetics for each flavonoid, results of which are presented 
in Figure 3. 
 While for the most flavonoids the rate of inactivation 
was assessed at 0, 1, 5, 10, 15 and 20 µM final 
concentration in flavonoid incubation, due to its low IC50 
value, concentrations for chrysin were adjusted to 0.01, 
0.1, 1, 5 and 10 µM.  
 The lowest inhibition constant was found for chrysin, 
with a value of 0.6 ± 0.3 µM. A flavanone analogue of 
chrysin – pinocembrin had a higher value of 1.2 ± 0.3 µM, 
with a much lower value of inhibition rate of 0.018 ± 0.001 
min–1 compared to chrysin (0.065 ± 0.005 min–1). 
Hydroxylated and methoxylated chrysin derivatives, i.e. 
apigenin and acacetin had higher values of inhibition 
constant: 1.5 ± 0.8 µM and 6 ± 3 µM, respectively, while 
their inhibition rate constants were 0.11 ± 0.01 min–1 and 
0.036 ± 0.006 min–1. 
 Consequently, inactivation efficacy was the highest 
for chrysin, 0.108 min–1 µM–1. This was followed by apigenin 
(0.073 min–1 µM–1), pinocembrin (0.015 min–1 µM–1) and 
acacetin (0.006 min–1 µM–1). In comparison, one of the  
well-known time dependent cytochrome P450 3A4 
inhibitors, mibefradil, shows an inactivation efficacy of 
0.174 min–1 µM–1.[33] This antihypertensive drug has been 
retracted from market due to clinically significant inter-
actions it caused with over 30 drugs in the market. 
 Extrapolation of the inactivation kinetic data 
obtained in the herein study is not straightforward. The 
setup of the experiment enables us to characterize 
observed metabolism/time dependent inhibition. Other 
parameters can also influence the results, e.g. some drugs 
can act as substrates and inhibitors at the same time.[3] 
However, based on previous reports by Benković et al.,[34,35] 
metabolism of acacetin, apigenin, chrysin and pinocembrin 
mediated by cytochrome P450 3A4 can be disregarded. 
Acacetin is susceptible to O-demethylation and aromatic 
hydroxylation, generating two products, apigenin and 
luteolin, which is attributed to cytochromes P450 1A2 and 
2D6; apigenin undergoes aromatic hydroxylation to luteolin 
and this is mediated by cytochrome P450 1A2; chrysin is 
aromatically monohydroxylated to baicalein or norvogonin 
or dihydroxylated to luteolin, and this is mediated to some 
extent by cytochrome P450 1A2; while pinocembrin was 
not found to be susceptible to the metabolism mediated by 
hepatic cytochromes P450.[34,35] 
 Usually, observed time-dependent inhibition is at 
the same time metabolism-dependent, meaning that 
cytochrome P450 generates a reactive intermediate that 
inactivates the enzyme (suicide substrates).[3] It can be 
speculated that this could be due to generation of a 
reactive epoxide on an aromatic ring and further research 
 
 
Figure 3. Inhibition kinetic parameters for each of the analysed flavonoids: KI – inhibition constant, kinact – inhibition rate 
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should focus on determining the structure of the reactive 
intermediate. However, this is not an easy task, as the 
inhibition rate constant of chrysin is 0.065 ± 0.005 min–1. 
Incubations are usually limited to 30 minutes, as longer 
incubations can result in hydrogen peroxide formation due 
to futile catalytic cycles. Hydrogen peroxide is known to 
destroy the heme moiety in the active site of the enzyme. 
Consequently, in half an hour, under maximal inhibition 
rate, in an incubation with 5 pmol of enzyme only 9.75 pmol 
of the reactive intermediate would be generated. That 
means that in an incubation in which 10 µM chrysin is 
present (concentration that enables maximal inhibition 
rate), around 100 nM of the reactive intermediate would 
be generated (1 ‰). Not surprisingly, even for the 
aforementioned mibefradil, the reactive intermediate has 
not been trapped nor was its structure described.[3] 
 To put the obtained results into perspective, an 
assessment parameter R can be calculated as per Food and 
Drug Administration guidelines.[13] For time-dependent 
inhibition R = (kobs + kdeg) / kdeg where kobs = (kinact × 50 × Imax) 
/ (KI + 50 × Imax); kobs is the observed inhibition rate constant 
of the affected enzyme, kdeg is the apparent degradation 
rate constant of the affected enzyme (0.0138 h–1 for 
cytochrome P450 3A4)[36], KI is inhibition constant – the 
inhibitor concentration causing half-maximal inactivation 
(0.6 µM), kinact is the inhibition rate constant (0.065 min–1), 
and Imax is the maximal unbound plasma concentration of 
the interacting drug at steady state (12 nM for chrysin)[9]. 
Thus, assessment parameter R has a value of 142, well 
above the threshold of 1.25, and consequently further 
assessment and pharmacokinetic modeling is needed to 
evaluate if this inhibition is clinically significant.  
 Based on the inhibition kinetic data, it can be 
assumed that interactions with herein studied flavonoids 
will be clinically significant at the level of metabolic enzyme 
cytochrome P450 3A4. In vivo data on apigenin in animal 
models confirm this observation.[37,38] The inhibition effect 
of apigenin against cytochrome P450 3A4 mediated 
metabolism was confirmed in rats when combined with 
etoposide. Etoposide is metabolized primarily by 
cytochrome P450 3A4 and, in the presence of apigenin, 
bioavailability of oral etoposide in rats was increased. This 
interaction does not necessarily need to be unwanted,  
as combined use of apigenin might be helpful to  
improve etoposide bioavailability in chemotherapeutic 
applications.[37] Imatinib, another chemotherapeutic agent, 
is metabolized by cytochrome P450 3A4 and it has been 
shown that in the short term apigenin can increase imatinib 
concentration in vivo in rats as an animal model.[38] 
 The major contribution of this study is charac-
terization of inhibition kinetics of cytochrome P450 3A4 by 
selected flavonoids that show metabolism dependent 
inhibition i.e. inactivation of the enzyme. Further in vitro 
studies can be conducted on different enzyme sources (e.g. 
tissue, liver microsomes) or using other marker substrates 
of cytochrome P450 3A4 (e.g. midazolam, nifedipine). The 
data from this study can be used to assess flavonoid-drug 
or food-drug interactions. While the data suggest that 
clinically significant interaction can exist, further 
assessment is needed through pharmacokinetic modeling 
or in vivo models to confirm the relevance of the results.[13]  
 
CONCLUSION 
Acacetin, apigenin, chrysin and pinocembrin cause time-
dependent inhibition of cytochrome P450 3A4. IC50 value is 
the lowest for chrysin, indicating that hydrophobicity of the 
nonsubstituted B ring, as well as rigidity of the structure 
(absence of a single bond between C2 and C3 atoms), plays 
an important role in the inhibition. Based on the data for 
inactivation kinetics, it can be concluded that chrysin has 
the highest potential to cause food-drug interactions when 
used with foods rich in this flavonoid, e.g. honey and 
propolis. Further in vitro studies are needed to determine 
the reactive intermediate responsible for inactivation of 
cytochrome P450 3A4 enzyme, as well as in vivo studies to 
determine possible clinical significance of this inhibition. 
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